
Vivesto Investor Relations Material
Latest events

R&D Update
Vivesto

Q1 2025
8 May, 2025

Q4 2024
20 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Vivesto
Access all reports
Vivesto AB develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. The company offers XRP988/Apealea/Doxophos that is a drug consisting of doxorubicin encapsulated in an oil-based carrier system for injection; and Paclical/Apalutamide that is an oral formulation of a pure antiandrogen. It serves various markets through third party distributors. The company was formerly known as Oasmia Pharmaceutical AB and changed its name to Vivesto AB in March 2022. The company was founded in 1988 and is headquartered in Solna, Sweden.
Latest articles
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
Ticker symbol
VIVE
Country
🇸🇪 Sweden